Cell-based therapies offer enormous promise to address unmet medical needs in a wide range of disease areas. Among all the different cell types, Mesenchymal Stem Cells (MSCs) present unique features for treating a wide variety of diseases.

Growing data suggest that the therapeutic advantages of mesenchymal stem cells are attributable to the release of soluble components and exosomes, which play an essential role in governing the immune response. Exosomes are tiny vesicles released by MSCs having the potential to serve as the “ideal drug delivery vehicle” due to their desirable properties such as low immunogenicity, ability to transport molecules effectively, precise interaction with target cells, but most importantly, their ease of manipulation for personalized medicine.

In the last decade, Cell for Cells has extensively researched MSCs derived from umbilical cord tissue, known to be the youngest and fittest stem cells and their exosomes. The company possesses a significant portfolio of allogeneic cell and exosome therapies for multiple indications. These products are manufactured in our ISO 9001-certified GMP Lab.

The cell therapy field is a relatively young business sector with just a few MSCs- and exosome-related therapeutic products which have reached the market and demonstrated their true medical and commercial potential. This reality places Cells for Cells’ products in a remarkable position to generate value for patients, industry partners, and investors.